Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04906876
Recruitment Status : Withdrawn (IND withdrawn)
First Posted : May 28, 2021
Last Update Posted : July 28, 2021
Sponsor:
Collaborator:
Actuate Therapeutics Inc.
Information provided by (Responsible Party):
Brown University

Brief Summary:

9-ING-41 in combination with gemcitabine and docetaxel will lead to sustained disease control and/or increase the rates of objective response in patients with unresectable or metastatic soft tissue and bone sarcomas.

This is an open label, two-stratum, phase 2 clinical trial evaluating the efficacy of 9-ING-41 in combination with gemcitabine/docetaxel in patients ≥10 years of age with advanced sarcoma.

Stratum A: Patients with advanced soft tissue sarcoma previously treated with 0-3 prior lines of systemic therapy will receive 9-ING-41 twice weekly with gemcitabine on days 1 and 8 and docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.

Stratum B: Patients with relapsed or refractory bone sarcoma previously treated with at least one line of systemic therapy will receive 9-ING-41 twice weekly with gemcitabine on days 1 and 8 and docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.

Disease response assessment will be performed every 2 cycles (6 weeks) for the first 8 cycles (24 weeks), then every 12 weeks thereafter.


Condition or disease Intervention/treatment Phase
Sarcoma Soft Tissue Sarcoma Metastatic Sarcoma Undifferentiated Pleomorphic Sarcoma Myxofibrosarcoma Leiomyosarcoma Liposarcoma Angiosarcoma Synovial Sarcoma Rhabdomyosarcoma Spindle Cell Sarcoma High Grade Sarcoma Bone Sarcoma Drug: Gemcitabine Drug: Docetaxel Drug: 9-ING-41 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
Estimated Study Start Date : September 2021
Estimated Primary Completion Date : July 2022
Estimated Study Completion Date : July 2025


Arm Intervention/treatment
Experimental: Stratum A: Soft Tissue Sarcoma
Patients with advanced soft tissue sarcoma previously treated with 0-3 prior lines of systemic therapy will receive 15 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
Drug: Gemcitabine
Gemcitabine as a 90-minute IV infusion

Drug: Docetaxel
Docetaxel as a 60-minute IV infusion

Drug: 9-ING-41
9-ING-41 as an IV infusion over 1-4 hours twice weekly

Experimental: Stratum B: Bone Sarcoma
Patients with relapsed or refractory bone sarcoma previously treated with at least one line of systemic therapy will receive 15 mg/kg 9-ING-41 twice weekly with 900 mg/m2 gemcitabine on days 1 and 8 and 75 mg/m2 docetaxel on day 8 of a 21-day cycle until disease progression or unacceptable toxicity.
Drug: Gemcitabine
Gemcitabine as a 90-minute IV infusion

Drug: Docetaxel
Docetaxel as a 60-minute IV infusion

Drug: 9-ING-41
9-ING-41 as an IV infusion over 1-4 hours twice weekly




Primary Outcome Measures :
  1. Disease Control Rate [ Time Frame: Approximately 24 weeks ]
    To determine the Disease Control Rate (DCR = Complete Response [CR] + Partial Response [PR] + Stable Disease [SD] at 6 months) of 9-ING-41 in combination with gemcitabine and docetaxel in advanced sarcoma.


Secondary Outcome Measures :
  1. Progression Free Survival [ Time Frame: From start of protocol therapy, approximately 5 years ]
    To determine the activity of 9-ING-41 with chemotherapy by assessing progression free survival (PFS).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   10 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Stratum A: Patients must have histologically confirmed grade 2 or 3 soft tissue sarcoma that is locally advanced and unresectable, or metastatic, consisting of one of the following subtypes: undifferentiated pleomorphic sarcoma (malignant fibrous histiocytoma), myxofibrosarcoma, leiomyosarcoma, liposarcoma (excluding well-differentiated), angiosarcoma, synovial sarcoma, rhabdomyosarcoma, spindle cell sarcoma and high-grade sarcoma NOS.
  • Stratum B: Patients must have histologically confirmed bone sarcoma that is relapsed or refractory following front-line therapy consisting of one of the following subtypes: osteosarcoma and Ewing sarcoma.
  • Patients must have at least one site of measurable disease by RECIST 1.1. See Section 12 (Measurement of Effect) for the evaluation of measurable disease.
  • Stratum A: No more than three prior lines of systemic therapy. Of note, anthracycline-based chemotherapy is generally considered first-line therapy. Previously untreated patients may be enrolled at the discretion of the treating investigator.
  • Stratum B: At least one prior line of systemic therapy.
  • Age ≥10 years.
  • Lansky score ≥50 for patients <16 years or ECOG performance status ≤2 for patients ≥16 years (Karnofsky ≥50%, see Appendix A).
  • Life expectancy of greater than 12 weeks.
  • Patients must have adequate organ and marrow function as defined below:

    • Hemoglobin ≥8 g/dl
    • absolute neutrophil count ≥1,000/mcL
    • platelets ≥100,000/mcL (transfusion independent)
    • total bilirubin ≤1.5x institutional upper limit of normal (ULN) (<3.0 mg/dL and direct bilirubin <1.5 mg/dL if documented Gilbert's syndrome)
    • AST(SGOT)/ALT(SGPT) ≤3x institutional ULN (≤ 5 x ULN if liver metastases present)
    • creatinine ≤1.5x institutional ULN OR
    • glomerular filtration rate (GFR) ≥50 mL/min/1.73 m2
    • PT/INR ≤1.5x institutional ULN
    • Amylase and lipase ≤1.5x institutional ULN
  • Washout period prior to Cycle 1, Day 1:

    • ≥ 21 days since last dose of chemotherapy, immunotherapy, or therapeutic radiation treatment.
    • ≥ 28 days since last tyrosine kinase inhibitor (or 5 half-lives, whichever is shorter).
    • ≥ 7 days since last focal palliative radiation treatment.
    • ≥ 28 days since major surgical procedure.
  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
  • Women of child-bearing potential must have a negative serum or urine pregnancy test at registration and within 7 days of first study therapy.
  • The effects of 9-ING-41 on the developing human fetus are unknown. For this reason and because other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Women may not be breastfeeding during study participation. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 90 days after completion of 9-ING-41 administration.
  • Patients must agree to provide tumor tissue, either fresh or archival specimen of primary tumor and/or metastatic lesion. If tumor tissue is not available, then discuss with principal investigator.
  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Patients with sarcoma histologies other than those listed above will be excluded.
  • Prior treatment with 9-ING-41, gemcitabine, or docetaxel.
  • Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1) with the exception of alopecia.
  • Patients who are receiving any other investigational agents for treatment of their sarcoma.
  • Patients who are pregnant or lactating.
  • Patients with untreated brain or meningeal metastases. Subjects with history of metastases are eligible provided they do not require ongoing steroid treatment and have shown clinical and radiographic stability for at least 14 days after definitive therapy.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to 9-ING-41, gemcitabine, docetaxel, or other agents used in study.
  • Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Has had a previous (within 2 years) or has a current malignancy other than the target cancer with the exception of curatively treated local tumors including carcinoma in situ of the breast or cervix, basal or squamous cell carcinoma of the skin, or prostate cancer with Gleason Grade < 6 and prostate-specific antigen within normal range.
  • Has any medical and/or social condition that, in the opinion of the investigator would preclude study participation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04906876


Locations
Layout table for location information
United States, Rhode Island
Hasbro Children's Hospital
Providence, Rhode Island, United States, 02903
Lifespan Cancer Insitute
Providence, Rhode Island, United States, 02903
Sponsors and Collaborators
Brown University
Actuate Therapeutics Inc.
Investigators
Layout table for investigator information
Principal Investigator: Bradley DeNardo, MD Brown University
Principal Investigator: Don S Dizon, MD Lifespan Cancer Institute
Layout table for additonal information
Responsible Party: Brown University
ClinicalTrials.gov Identifier: NCT04906876    
Other Study ID Numbers: BrUOG 398
First Posted: May 28, 2021    Key Record Dates
Last Update Posted: July 28, 2021
Last Verified: July 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Rhabdomyosarcoma
Sarcoma
Leiomyosarcoma
Liposarcoma
Sarcoma, Synovial
Hemangiosarcoma
Histiocytoma, Malignant Fibrous
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Myosarcoma
Neoplasms, Muscle Tissue
Neoplasms, Adipose Tissue
Neoplasms, Connective Tissue
Neoplasms, Vascular Tissue
Histiocytoma
Neoplasms, Fibrous Tissue
Gemcitabine
Docetaxel
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Tubulin Modulators